9 results about "Butyrolactone I" patented technology

The application discloses a kind of Baeyer-Villiger monooxygenase and its mutant in synthesis optical pure 3-substituted chiral butyrolactone Application, the application with the Baeyer-Villiger monooxygenase ArBVMO of Acinetobacter radioresistens (CGMCC No.25186) source of resistance to radiation Acinetobacter (Acinetobacter radioresistens) and its mutant as biocatalyst, can catalyze the asymmetric oxidation of series latent chiral 3-substituted cyclobutanone, preparation corresponding optical pure chiral butyrolactone.Compared with prior art, the application has the advantages of high enzyme reaction substrate concentration, mild reaction condition, environment-friendly, high space-time yield, high product optical purity, and has good application prospect.

The present application relates to a kind of biological gamma-butyrolactone and its production method, the production method of biological gamma-butyrolactone of the present application includes the following steps: preparation biological succinic acid solution;The obtained biological succinic acid solution and hydrogen continuously enter the fixed bed containing nickel copper catalyst and carry out hydrogenation reaction, obtain crude product;The obtained crude product enters separation column and is separated and purified, obtain biological gamma-butyrolactone;Nickel loading in the nickel copper catalyst is 30wt%~60wt%, copper loading is 1wt%~5wt%, the content of hydrophobic compound is 0.01wt%~0.2wt%.The present application is prepared by 5wt%~30wt% biological 1,4-butanedioic acid dilute solution continuously into fixed bed hydrogenation reactor, and biological gamma-butyrolactone liquid is prepared, continuously enters rectification separation column and is separated, and biological gamma-butyrolactone product with purity ≥99.99% can be prepared, and the rest is impurity;The impurity includes tetrahydrofuran and 1,4-butanediol;The content of tetrahydrofuran is ≤0.004%;The content of 1,4-butanediol is ≤0.005%.

The invention relates to a process for production and / or storage of α-methylenelactones, wherein a α- methylenelactone is present in a vessel, the α-methylenelactone is a α-methylenelactone of the following Formula I: and R1 is hydrogen, or a C1 to C10, in particular C1 to C5, linear or branched alkyl group, in particular R1 is hydrogen or a methyl group, and the vessel contains a gaseous phase and a liquid phase, wherein the gaseous phase comprises less than 15 vol.-%, based on the total gaseous phase, of oxygen, and the liquid phase comprises - 50.0000 wt.-% to 99.9995 wt.-%, based on the total liquid phase, of the α-methylenelactone, - 0.0000 wt.-% to 49.9995 wt.-%, based on the total liquid phase, of residuals, in particular carboxylic acids such as itaconic acid, hydroxycarboxylic acids such as 2-methylene-4-ol-butyric acid, hydroxycarboxylic esters such as γ-butyrolactone, water, further monomers, and / or organic solvents, and - 0.0005 wt.-% to 0.2000 wt.-%, based on the total liquid phase, of a polymerization inhibitor, wherein the polymerization inhibitor is an aminoxyl radical of the following Formular II: and R2 is hydrogen, oxygen, OH NH2, OMe or an alkyl-, ester- or amide group, wherein the polymerization inhibitor is in particular 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl.

The invention provides a method for synthesizing alpha-bromo-gamma-butyrolactone, which comprises the following step: by using 1-propyl phosphoric anhydride or 1-butyl phosphoric anhydride as a catalyst, reacting a substrate gamma-butyrolactone with a bromination reagent to obtain the alpha-bromo-gamma-butyrolactone. According to the method, the used raw material gamma-butyrolactone is cheap and easy to obtain, the route is short, the operation is convenient, the finally obtained by-products are few and easy to treat and purify, and the product with higher purity can be obtained without rectification.

The application belongs to the technical field of medicine synthesis, and particularly relates to an alpha-methenyl-gamma-butyrolactone compound and an asymmetric kinetic resolution synthesis method thereof. The compound provided by the application is shown as formula I. The application provides a simple, efficient and alpha-methenyl-gamma-butyrolactone compound synthesis method. The series of compounds prepared have good antitumor activity and good application prospect.

The present application relates to an ene reductase mutant and its application in the synthesis of chiral aromatic polysubstituted gamma-butyrolactone. The ene reductase mutant is a protein formed by replacing the tryptophan at position 100 of the amino acid sequence shown in SEQ ID No. 2 with alanine. The present application provides a new ene reductase mutant SsER-A314Y / W100A, and a double enzyme cascade catalytic system is constructed with the mutant SsCR-V3 (V126A / N210H / M215G) of the carbonyl reductase SsCR for the efficient stereoselective synthesis of various aromatic chiral gamma-butyrolactone. Compared with the prior art, the aromatic chiral gamma-butyrolactone double enzyme cascade system provided by the present application has the significant advantages of simple process, high atom economy, high optical purity of product and environmental friendliness, and has good industrial application prospect.

The invention belongs to the technical field of biological medicines, and discloses application of a deep-sea butyrolactone compound in preparation of a product for preventing and / or treating hyperuricemia and / or uric acid nephropathy. The butyrolactone compound disclosed by the invention is specifically 5-acetyl-3-hydroxy-4-(4-hydroxyphenyl)-5-[4-methyl-3-(3-methylbutyl-2-ene-1-yl) benzyl] furan-2 (5H)-ketone, and the structural formula of the butyrolactone compound is shown in the description. It is proved for the first time that the butyrolactone compound has the capacity of remarkably improving hyperuricemia and uric acid nephropathy, and the blood uric acid level, the serum creatinine level and the blood urea nitrogen level of hyperuricemia mice induced by oteracil potassium and hypoxanthine and uricase knockout mice are remarkably improved; the compound can be applied to preparation of products for preventing and / or treating the hyperuricemia and / or the uric acid nephropathy, a new product is provided for prevention and treatment of the hyperuricemia and the uric acid nephropathy, and therefore the compound has a wide application prospect.

A method for preparing gamma-butyrolactone including converting furoic acid to the gamma-butyrolactone in an undivided cell without a mediator for paired electrolysis, including the steps of: a) electrochemically oxidizing the furoic acid to 2(5H)-furanone; and b) electrochemically reducing the 2(5H)-furanone to the gamma-butyrolactone.

The application discloses synthesis of a sparteine derivative ligand and application of the sparteine derivative ligand in preparation of chiral beta-butyrolactone, and specifically, the sparteine derivative ligand is prepared from sparteine, a catalyst is prepared in situ from the sparteine derivative ligand and a metal iridium precursor, and the catalyst is used for catalyzing asymmetric hydrogenation of a double ethylene ketone to synthesize chiral beta-butyrolactone. The synthesis route of the ligand is simple, the catalyst has high activity and low cost, and the chemical selectivity and the stereoselectivity are very high, so that the production cost of the beta-butyrolactone is greatly reduced.